Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019158 (
hepatitis
)
30,205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
XAGE-1
is classified into the group of a new family of cancer-testis antigens (CTA) and has the four transcript variants of XAGE-1a,
XAGE-1b
,
XAGE-1c
and
XAGE-1d
. Immunohistochemistry was used to investigate the expression of
XAGE-1
transcript variants in Chinese patients with hepatocellular carcinoma (HCC). Reverse transcription-polymerase chain reaction (RT-PCR) and real-time RT-PCR were used to analyze
XAGE-1
gene expression, and
XAGE-1
protein expression was examined by immunohistochemistry. Furthermore, the clinical correlation of
XAGE-1
expression was analyzed. The expression of the
XAGE-1
mRNA was investigated in the tissues of 96 HCC patients and all
XAGE-1
isoforms were detected in these tissues. Three types of
XAGE-1
transcript variants (
XAGE-1b
,
XAGE-1c
and
XAGE-1d
) showed high specific and frequent expression in HCC tissues, with the positive expression rate of
XAGE-1b
,
XAGE-1c
and
XAGE-1d
being 41.7% (40/96), 15.6% (15/96) and 26.0% (25/96), respectively.
XAGE-1b
was the dominant type, but none of the three were detected in adjacent non-HCC tissues. Only 2 cases of XAGE-1a mRNA expression were observed. Moreover,
XAGE-1
protein was detected in 39 of 96 HCC patients, but none in the adjacent non-cancerous tissue and normal liver tissue. No relationship was found between the expression of
XAGE-1
and clinical parameters, such as age, gender, tumor size, TNM staging, serum AFP level and infection with
hepatitis
virus. Patients with
XAGE-1b
-positive transcript variant exhibited shorter 2-year survival times. The high frequency and specificity of
XAGE-1
, particularly
XAGE-1b
, in HCC indicates that their products may predict the prognosis of HCC patients and be novel targets for antigen-specific immunotherapy to HCC.
...
PMID:Hepatocellular carcinoma patients highly and specifically expressing XAGE-1 exhibit prolonged survival. 2287 Jan 17
